PubMed Health⌕ Search

Biomedical subjects

T Rozmysłowicz

Publications and source records attributed to T Rozmysłowicz.

10 recordsLinked to original sources
PubMed1996

Comparison of the different strategies for cryopreserving and storage of the bone marrow CD34+ cells. Possibility of unprogrammed rate freezing and storage at -80 degrees C mechanical freezer.

We have compared the efficiency of the different strategies allowing for a long term storage of a human CD34+ bone marrow cells. Accordingly, the aliquots of CD34+ cells isolated from bone marrow were frozen using: controlled rate freezing equipment, or freezer unprogrammed in a -80 degrees C mechanical freezer. After freezing, CD34+ cells were subsequently stored for one month in a liquid nitrogen tank at -196 degrees C or in mechanical freezer at -80 degrees C. We have found that both the viability and the recovery of clonogeneic progenitors of CD34+ cells samples stored at different temperature were similar. Therefore, regarding the costs and simplicity, we recommend the unprogrammed freezing and storage of human CD34+ cells at -80 degrees C in a mechanical freezer as a convenient, inexpensive, and reliable method for storing marrow for transplantation. This data also indirectly indicate that the aliquots of the CD34+ cells can be shipped frozen on dry ice (-80 degrees C), and that these cells will maintain viability under this conditions. Furthermore, in this study we have confirmed validity of our earlier observation that human CFU-Meg progenitors are more sensitive to cryopreservation.

Antigens, CD↗
PubMed1991

[Effect of thioproline in vitro on selected functions of peripheral blood lymphocytes from healthy persons and patients with lympho- proliferative syndromes].

Thioproline (thiazolidino-4-carboxylic acid) is one of promising antineoplastic preparations arousing interest since several years. In view of controversies with respect to the mechanism of thioproline action it was tried to study the effects of the preparation on certain functions of lymphocytes. The experimental model included cultures of T and B lymphocytes obtained from 20 healthy blood donors. The cultures were exposed to various concentrations of thioproline for determining the incorporation of 3H-thymidine into the DNA of these cells, their viability and intracellular concentrations of cAMP and cGMP. The lymphocytes from these healthy donors served also as a control for B-cells isolated from 24 patients with lymphoproliferative syndromes. It was found that at low concentrations thioproline added to the culture of T-cells from healthy donors caused a slight increase of 3H-thymidine incorporation, but at high concentrations a strong cytotoxic effect on T-cells was noted. B-cells isolated from the peripheral blood of healthy subjects and from the patients were highly sensitive to thioproline. These observations demonstrated a cytotoxic effect of thioproline on T and B lymphocytes.

Adolescent↗
PubMed1991

[Preliminary results of the treatment of acute leukemia with mitoxantrone].

Mitoxantrone is a new anthracenodione derivative with a high antineoplastic activity in proliferative diseases of the haemopoietic system. In the Institute of Haematology in Warsaw and in the Department of Haematology, Silesian Medical Academy in Katowice this agent was used in combination with cytarabine in 49 cases of acute leukaemia (35 with acute myeloid leukaemia and 14 with acute lymphoblastic leukaemia). The preparations used were Mitoxantrone (POLFA Works in Jelenia Góra) and Novantrone (Lederle). These agents were given intravenously in doses of 10-20 mg/m2 for 3 days in combination with cytarabine in three doses: 100 mg/m2 on days 1 through 7, and 1 g/m2 or 3 g/m2 every 12 hours on days 1 through 4 of the treatment. Complete remission was obtained in 17 cases (35%), including 13 with acute myeloid leukaemia (37%) and 4 with acute lymphoblastic leukaemia (29). The most frequent side effects were: long-lasting pancytopenia (in 100% of cases), hair loss (39%) and gastrointestinal toxicity (33%). No significant differences were noted in the effectiveness and toxicity between these two preparations. In the light of the presented results it may be accepted that the combination of mitoxantrone with cytarabine is an important advance in the treatment of acute leukaemias.

Adolescent↗
PubMed1980

Influence of immunosuppressive pretreatment on the survival of mice challenged with Ehrlich ascites carcinoma (EAC).

Mice were pretreated with immunosuppressive doses of cyclophosphamide (CY), cortisone acetate (CA) or X-irradiation. 24 h later all mice were given 1 x 10(5) EAC cells intraperitoneally. In another experiment mice were splenectomized 1 h before injection of EAC cells. Neither CY nor CA pretreatment had significant influence on the survival of tumor-inoculated mice. On other hand, X-irradiation or splenectomy strengthened tumor resistance.

Animals↗
PubMed1979

In vivo activity of spleen cells from untreated syngeneic mice against Ehrlich ascites carcinoma.

Inbred CFW/L1 or BALB/c male mice were injected intraperitoneally with 1 X 10(5) EAC cells. They died in 98.6 or 100%, respectively, within 100 days of observation. Intraperitoneal injection of 6 X 10(7) syngeneic spleen cells from 6--9-week-old CFW/L1 or BALB/c donors 2.5--4 h after tumour inoculation significantly prolonged MST and 16.7 or 23.5% of mice, respectively, survived for 100 days. Smaller amounts of spleen cells, thymus cells, mixed spleen and thymus cells, or spleen cells from older donors did not show this effect. Homogenized spleen cells were also inactive. Antitumour activity of spleen cells was still evident when they were isolated from irradiated (2 000R) donors or were given 24 h after tumour inoculation. Spleen cells used for in vivo studies showed spontaneous cytotoxic activity in vitro against EAC cells in the 51Cr-release cell-mediated cytotoxicity test. The possible participation of NK cells in the observed in vivo antitumour activity of normal spleen cells is discussed.

Animals↗
PubMedDate not supplied

[Thrombocytopenia in a patient with hemophilia and HIV infection treated with intravenous immunoglobulin and splenectomy].

In a patient with haemophilia B who had developed immune thrombocytopenia following HIV infection, high doses of intravenous immunoglobulin were administered. The therapy brought about only a temporary rise in platelet counts. No beneficial effects were also obtained during a 3-month treatment with corticosteroids. Since there was no response to the conservative therapy, the patient was splenectomized under the cover of factor IX concentrate and the surgical procedure resulted in a complete remission of the thrombocytopenia.

Acquired Immunodeficiency Syndrome↗